Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499428 | 0.91 | KMT2A (0.46) | MGLLTSHRKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5852228 | 0.85 | CA2 (0.46) | KMT2AL3MBTL1ALDH1A1MAPK1HPGD | |
| SCHEMBL20530034 | 0.83 | KMT2A (0.41) | MGLLKMT2AL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL15896085 | 0.83 | KMT2A (0.44) | KMT2AL3MBTL1MAPTALDH1A1MAPK1 | |
| SCHEMBL17356716 | 0.83 | KMT2A (0.41) | MGLLKMT2AL3MBTL1LMNAMAPT | |
| SCHEMBL2450503 | 0.83 | KMT2A (0.57) | MGLLTSHRKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL31225828 | 0.81 | CTBP2 (0.47) | KMT2AMAPTALDH1A1 | |
| SCHEMBL24969572 | 0.81 | KMT2A (0.46) | KMT2AL3MBTL1LMNAMAPTALDH1A1 | |
| SCHEMBL4738882 | 0.81 | LMNA (0.51) | TSHRKMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL31225518 | 0.81 | SMN1; SMN2 (0.54) | POLBKMT2AATML3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-5187195-A | Vasodilators; endothelin agonists; 1,7,12-trioxo,3-methyl, 4a,8,12a,12b-tetrahydroxy,6a-(2-amino-2-acylethylthio)-1,4, 4a,5,6,6a,7,12,12a,12b-decahydroanthroquinones | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-16 | — | — | US | disclosed |
| EP-0405421-A2 | Anthraquinone derivatives and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | MGLL 2499/4885POLB 4353/4885TSHR 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.